Delving into the Latest Updates on Banyu Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Infectious Diseases

Small molecule drug

Synthetic peptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	4
Synthetic peptide	1

Top 5 Target	Count

ETB(Endothelin receptor type B)	1
PBPs(Bacterial penicillin-binding protein)	1
OOR(Nociceptin receptor)	1
mGluR1(Metabotropic glutamate receptor 1)	1
Na/K-ATPase(Sodium/potassium-transporting ATPase)	1

A review.Schizophrenia is a psychiatric disorder whose symptoms the many show in adolescence or adolescence, and it is known that incidence ratio is comparatively as high as about 1% of overall population.Although the condition of schizophrenia is variegated and it is not the most important, there is cognitive dysfunction, such as neg. symptoms, such as pos. symptoms, such as a hallucination and delusion, flattening of affect, volition decline, and social withdrawal, an attentiveness fall, and executive dysfunction, as cardinal symptoms.Although the existing schizophrenia curative medicine mainly has the antagonism to D₂ receptor and a 5-HT_2A receptor and it succeeds in a pos. symptom, an improvement action on neg. symptoms or cognitive dysfunction is not yet enough, and about 30% of schizophrenia patients still show drug resistance nature.Moreover, the necessity for development of the schizophrenia curative medicine which has a new mechanism from revealing side effects, such as extrapyramidal system condition, high prolactin symptom and weight gain, etc. has recited strongly.As one of them, the drug design what is called based on a glutamic acid hypothesis (NMDA receptor function fall hypothesis) that the abnormalities in glutamatergic neurotransmission of a frontal cortex are mainly the causes is activating.Now, glycine transporter-inhibitory drug, metabotropic glutamate receptor 2/3 type (mGluR2/3) agonist, a mGluR2 pos. allosteric modulator, etc. are during a clin. test.The metabotropic glutamate receptor 1 type (mGluR1) as a baguette, and have advanced drug design of the antagonistic drug.In this paper, new mGluR1 antagonistic it gives an outline focusing on a relation with the evaluation and the receptor share about the validity and the side effects in the feature and its schizophrenia animal model of drug and possibility as a new schizophrenia curative medicine of mGluR1 antagonistic drug is considered.

01 Jan 2013·Endocrine JournalQ4 · MEDICINE

Effects of celiac superior mesenteric ganglionectomy on glucose homeostasis and hormonal changes during oral glucose tolerance testing in rats

Q4 · MEDICINE

Article

Author: Eiki, Jun-ichi ; Kikuchi, Masatoshi ; Notoya, Yoko ; Shikuma, Junpei ; Odawara, Masato ; Ogihara, Norikazu ; Kanazawa, Masao ; Kumakura, Atsushi

The liver plays an important role in maintaining glucose homeostasis in the body. In the prandial state, some of the glucose which is absorbed by the gastrointestinal tract is converted into glycogen and stored in the liver. In contrast, the liver produces glucose by glycogenolysis and gluconeogenesis while fasting. Thus, the liver contributes to maintaining blood glucose level within normoglycemic range. Glycogenesis and glycogenolysis are regulated by various mechanisms including hormones, the sympathetic and parasympathetic nervous systems and the hepatic glucose content. In this study, we examined a rat model in which the celiac superior mesenteric ganglion (CSMG) was resected. We attempted to elucidate how the celiac sympathetic nervous system is involved in regulating glucose homeostasis by assessing the effects of CSMG resection on glucose excursion during an oral glucose tolerance test, and by examining hepatic glycogen content and hepatic glycogen phosphorylase (GP) activity. On the oral glucose tolerance test, CSMG-resected rats demonstrated improved glucose tolerance and significantly increased GP activity compared with sham-operated rats, whereas there were no significant differences in insulin, glucagon or catecholamine levels between the 2 groups. These results suggest that the celiac sympathetic nervous system is involved in regulating the rate of glycogen consumption through GP activity. In conclusion, the examined rat model showed that the celiac sympathetic nervous system regulates hepatic glucose metabolism in conjunction with vagal nerve innervations and is a critical component in the maintenance of blood glucose homeostasis.

01 Aug 2011·Journal of Diabetes InvestigationQ3 · MEDICINE

Effect of long-term treatment with a small-molecule glucokinase activator on glucose metabolism, lipid profiles and hepatic function

Q3 · MEDICINE

ArticleOA

Author: Eiki, Junichi ; Ohyama, Sumika ; Shimazaki, Hiroko ; Terauchi, Yasuo ; Nakamura, Akinobu

We investigated the long-term effect of a glucokinase (GK) activator (GKA) on the changes in hepatic gene expression, glucose metabolism, lipid profiles and hepatic function in wild-type mice and the haploinsufficiency of β-cell-specific GK mice on a high-fat (HF) diet. Twenty weeks of GKA treatment had no effect on hepatic GK activity or expression of genes related to glucose or lipid metabolism, suggesting that chronic GK activation by GKA showed a sustained reduction of ambient blood glucose levels without causing significant impact on hepatic lipid and glucose metabolisms. Furthermore, GKA exerted glucose-lowering efficacy lasted for up to 40 weeks without increasing bodyweight or exerting adverse effects on lipid metabolism or hepatic function in either genotype on the HF diet. The present results show that GKA is capable of chronically improving glucose metabolism in mice on the HF diet without exerting a harmful influence on their lipid profile or hepatic function. (J Diabetes Invest,doi: 10.1111/j.2040-1124.2011.00103.x, 2011).

100 Deals associated with Banyu Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Banyu Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

29

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ORL1 antagonists(Banyu Pharmaceutical) ( OOR )	-	Clinical
FTIDC ( mGluR1 )	-	Preclinical
AU-1421 ( Na/K-ATPase )	-	Preclinical
[125I]BQ-3020 ( ETB )	-	Preclinical
J-111347 ( PBPs )	Bacterial Infections More	Preclinical